Tumor-associated protein ligands recognized by human γδ T cell receptor and their implications in cancer therapy

Abstract

In recent years, immunologists have been working to utilize the functional mechanism of the immune system to research new tumor treatment methods and achieved a major breakthrough in 2013, which was listed as one of the top 10 scientific breakthroughs of 2013 by Science magazine (see “Cancer immunotherapy”. Science. 2013;342:1417. doi: 10.1126/science.1249481). Currently, two main methods are used in clinical tumor immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Clinical responses to checkpoint inhibitors rely on blockade of the target neoantigens expressed on the surfaces of tumor cells, which can inhibit T cell activity and prevent the T cell immune response; therefore, the therapeutic effect is limited by the tumor antigen expression level. While CAR-T cell therapy can partly enhance neoantigen recognition of T cells, problems remain in the current treatment for solid tumors, such as restricted transport of adoptively transferred cells to the tumor site and off-targets. Immunologists have therefore turned their attention to γδ T cells, which are not restricted by the major histocompatibility complex (MHC) for neoantigen recognition and are able to initiate a rapid immune response at an early stage. However, due to the lack of an understanding of the antigens that γδ T cells recognize, the role of γδ T cells in tumorigenesis and tumor development is not clearly understood. In the past few years, extensive data identifying antigen ligands recognized by γδ T cells have been obtained, mainly focusing on bisphosphonates and small-molecule polypeptides, but few studies have focused on protein ligands recognized by γδ T cells. In this paper, it is reviewed and analyzed that the tumor-associated protein ligands of γδ T cells that have been discovered thus far, hoping to provide new ideas for the comprehensive application of γδ T cells in tumor immunotherapy.

Keywords

γδ T cells / tumor-associated protein ligands / immunotherapy

References

[1] Muro R, Takayanagi H, Nitta T. T cell receptor signaling for γδ T cell development. Inflamm Regen. 2019; 39: 6.

[2] Cosway EJ, James KD, Lucas B, Anderson G, White AJ. The thymus medulla and its control of αβT cell development. Semin Immunopathol. 2021; 43: 15-27.

[3] Deniger DC, Moyes JS, Cooper LJ. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol. 2014; 5: 636.

[4] Fleming C, Morrissey S, Cai Y, Yan J. γδ T cells: unexpected regulators of cancer development and progression. Trends Cancer. 2017; 3: 561-70.

[5] Barsac E, de Amat Herbozo C, Gonzalez L, Baranek T, Mallevaey T, Paget C. Regulation and functions of protumoral unconventional T cells in solid tumors. Cancers (Basel). 2021; 13: 3578.

[6] Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. γδ T cells provide an early source of interferon γ in tumor immunity. J Exp Med. 2003; 198: 433-42.

[7] Li H, Xiang Z, Feng T, Li J, Liu Y, Fan Y, et al. Human Vγ9Vδ2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells. Cell Mol Immunol. 2013; 10: 159-64.

[8] Silva-Santos B, Mensurado S, Coffelt SB. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019; 19: 392-404.

[9] Qi J, Zhang J, Zhang S, Cui L, He W. Immobilized MICA could expand human Vδ γδ T cells in vitro that displayed major histocompatibility complex class I chain-related A-dependent cytotoxicity to human epithelial carcinomas . Scand J Immunol. 2002; 58: 211-20.

[10] Almeida AR, Correia DV, Fernandes-Platzgummer A, da Silva CL, da Silva MG, Anjos DR, et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin Cancer Res. 2016; 22: 5795-804.

[11] Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells. Eur J Cardiothorac Surg. 2010; 37: 1191-7.

[12] Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021; 18: 427-39.

[13] Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018; 26: 354-65.

[14] König R, Huang LY, Germain RN. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature. 1992; 356: 796-8.

[15] Maroto R, Shen X, König R. Requirement for efficient interactions between CD4 and MHC class II molecules for survival of resting CD4⁺ T lymphocytes in vivo and for activation-induced cell death . J Immunol. 1999; 162: 5973-80.

[16] Wu D, Wu P, Qiu F, Wei Q, Huang J. Human γδT-cell subsets and their involvement in tumor immunity. Cell Mol Immunol. 2017; 14: 245-53.

[17] Bonneville M, O’Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010; 10: 467-78.

[18] Bottino C, Tambussi G, Ferrini S, Ciccone E, Varese P, Mingari MC, et al. Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor. J Exp Med. 1988; 168: 491-505.

[19] Petrasca A, Melo AM, Breen EP, Doherty DG. Human Vδ3⁺ γδ T cells induce maturation and IgM secretion by B cells . Immunol Lett. 2018; 196: 126-34.

[20] Stolk D, van der Vliet HJ, de Gruijl TD, van Kooyk Y, Exley MA. Positive & negative roles of innate effector cells in controlling cancer progression. Front Immunol. 2018; 9: 1990.

[21] Mangan BA, Dunne MR, O’Reilly VP, Dunne PJ, Exley MA, O’Shea D, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells. J Immunol. 2013; 191: 30-4.

[22] Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid . Cancer Res. 2004; 64: 9172-9.

[23] Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14: 123-33.

[24] Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science. 1998; 279: 1737-40.

[25] Kabelitz D, Marischen L, Oberg HH, Holtmeier W, Wesch D. Epithelial defence by γδ T cells. Int Arch Allergy Immunol. 2005; 137: 73-81.

[26] Nedellec S, Sabourin C, Bonneville M, Scotet E. NKG2D costimulates human Vγ9Vδ2 T cell antitumor cytotoxicity through protein kinase Cθ-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol. 2010; 185: 55-63.

[27] Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol. 2007; 66: 320-8.

[28] Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol. 2005; 175: 2144-51.

[29] Lança T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity. Blood. 2010; 115: 2407-11.

[30] Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2D ligand ULBP4 binds to TCRγ9/δ2 and induces cytotoxicity to tumor cells through both TCR γδ and NKG2D. Blood. 2009; 114: 310-7.

[31] Hannani D, Ma Y, Yamazaki T, Déchanet-Merville J, Kroemer G, Zitvogel L. Harnessing γδ T cells in anticancer immunotherapy. Trends in Immunology. 2012; 33: 199-206.

[32] Farrington LA, Callaway PC, Vance HM, Baskevitch K, Lutz E, Warrier L, et al. Opsonized antigen activates Vδ2⁺ T cells via CD16/FCγRIIIa in individuals with chronic malaria exposure . PLoS Pathog. 2020; 16: e1008997.

[33] Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, et al. Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa). Blood. 2012; 119: 1418-27.

[34] Martinet L, Jean C, Dietrich G, Fournie JJ, Poupot R. PGE₂ inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling . Biochem Pharmacol. 2010; 80: 838-45.

[35] Maeurer M, Zitvogel L, Elder E, Storkus WJ, Lotze MT. Human intestinal Vδ1⁺ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA . Nat Immun. 1995; 14: 188-97.

[36] Beckman EM, Melián A, Behar SM, Sieling PA, Chatterjee D, Furlong ST, et al. CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. J Immunol. 1996; 157: 2795-803.

[37] Spada FM, Grant EP, Peters PJ, Sugita M, Melián A, Leslie DS, et al. Self-recognition of CD1 by γ/δ T cells: implications for innate immunity. J Exp Med. 2000; 191: 937-48.

[38] Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, et al. The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR. Eur J Immunol. 2012; 42: 2505-10.

[39] Harly C, Joyce SP, Domblides C, Bachelet T, Pitard V, Mannat C, et al. Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2. Sci Immunol. 2021; 6: eaba9010.

[40] Marlin R, Pappalardo A, Kaminski H, Willcox CR, Pitard V, Netzer S, et al. Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2. Proc Natl Acad Sci U S A. 2017; 114: 3163-8.

[41] Rice MT, von Borstel A, Chevour P, Awad W, Howson LJ, Littler DR, et al. Recognition of the antigen-presenting molecule MR1 by a Vδ3⁺ γδ T cell receptor . Proc Natl Acad Sci U S A. 2021; 118: e2110288118.

[42] Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T, et al. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol. 2012; 13: 872-9.

[43] Di Marco Barros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, et al. Epithelia use butyrophilin-like molecules to shape organ-specific γδ T cell compartments. Cell. 2016; 167: 203-18.e17.

[44] Davodeau F, Peyrat MA, Hallet MM, Gaschet J, Houde I, Vivien R, et al. Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors. J Immunol. 1993; 151: 1214-23.

[45] Panchamoorthy G, McLean J, Modlin RL, Morita CT, Ishikawa S, Brenner MB, et al. A predominance of the T cell receptor V gamma 2/V delta 2 subset in human mycobacteria-responsive T cells suggests germline gene encoded recognition. J Immunol. 1991; 147: 3360-9.

[46] Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature. 1995; 375: 155-8.

[47] Belmant C, Espinosa E, Poupot R, Peyrat MA, Guiraud M, Poquet Y, et al. 3-formyl-1-butyl pyrophosphate a novel mycobacterial metabolite-activating human γδ T cells. J Biol Chem. 1999; 274: 32079-84.

[48] Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003; 197: 163-8.

[49] Idrees AS, Sugie T, Inoue C, Murata-Hirai K, Okamura H, Morita CT, et al. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Sci. 2013; 104: 536-42.

[50] Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients . Clin Exp Immunol. 2010; 161: 290-7.

[51] Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007; 67: 7450-7.

[52] Chen ZW. Multifunctional immune responses of HMBPP-specific Vγ9Vδ2 T cells in M. tuberculosis and other infections . Cell Mol Immunol. 2013; 10: 58-64.

[53] Chen H, He X, Wang Z, Wu D, Zhang H, Xu C, et al. Identification of human T cell receptor γδ-recognized epitopes/proteins via CDR3δ peptide-based immunobiochemical strategy. J Biol Chem. 2008; 283: 12528-37.

[54] Salim M, Knowles TJ, Baker AT, Davey MS, Jeeves M, Sridhar P, et al. BTN3A1 discriminates γδ T cell phosphoantigens from nonantigenic small molecules via a conformational sensor in its B30.2 domain. ACS Chem Biol. 2017; 12: 2631-43.

[55] Yang Y, Li L, Yuan L, Zhou X, Duan J, Xiao H, et al. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated Vγ9Vδ2 T cell activation. Immunity. 2019; 50: 1043-53.e5.

[56] Rigau M, Ostrouska S, Fulford TS, Johnson DN, Woods K, Ruan Z, et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science. 2020; 367: eaay5516.

[57] Karunakaran MM, Willcox CR, Salim M, Paletta D, Fichtner AS, Noll A, et al. Butyrophilin-2A1 directly binds germline-encoded regions of the Vγ9Vδ2 TCR and is essential for phosphoantigen sensing. Immunity. 2020; 52: 487-98.e6.

[58] Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, et al. γ9δ2T cell diversity and the receptor interface with tumor cells. J Clin Invest. 2020; 130: 4637-51.

[59] Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020; 369: 942-9.

[60] Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012; 120: 2269-79.

[61] De Gassart A, Le KS, Brune P, Agaugué S, Sims J, Goubard A, et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Sci Transl Med. 2021; 13: eabj0835.

[62] Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, et al. Phase-I study of innacell γδ^TM, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma . Cancer Immunol Immunother. 2008; 57: 1599-609.

[63] Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, Guiraud M, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005; 22: 71-80.

[64] Kakeda K, Ishikawa H. Molecular chaperon produced by an intracellular symbiont. J Biochem. 1991; 110: 583-7.

[65] Todryk SM, Gough MJ, Pockley AG. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology. 2003; 110: 1-9.

[66] Laad AD, Thomas ML, Fakih AR, Chiplunkar SV. Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells. Int J Cancer. 1999; 80: 709-14.

[67] Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A. 1996; 93: 13629-34.

[68] Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, et al. The DNA-mismatch repair enzyme hMSH2 modulates UV-B-induced cell cycle arrest and apoptosis in melanoma cells. J Invest Dermatol. 2008; 128: 203-13.

[69] Atre N, Thomas L, Mistry R, Pathak K, Chiplunkar S. Role of nitric oxide in heat shock protein induced apoptosis of gammadeltaT cells. Int J Cancer. 2006; 119: 1368-76.

[70] Dai YM, Liu HY, Liu YF, Zhang Y, He W. EBV transformation induces overexpression of hMSH2/3/6 on B lymphocytes and enhances γδT-cell-mediated cytotoxicity via TCR and NKG2D. Immunology. 2018; 154: 673-82.

[71] Ghadially H, Brown L, Lloyd C, Lewis L, Lewis A, Dillon J, et al. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer. 2017; 116: 1208-17.

[72] Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006; 239: 22-30.

[73] Shetty P, Patil VS, Mohan R, D’souza LC, Bargale A, Patil BR, et al. Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer. Ann Clin Biochem. 2017; 54: 463-71.

[74] Sharma MC, Tuszynski GP, Blackman MR, Sharma M. Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer. Cancer Lett. 2016; 373: 27-35.

[75] Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, et al. Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring. Nat Biomed Eng. 2017; 1: 0021.

[76] Takasugi M, Okada R, Takahashi A, Chen VD, Watanabe S, Hara E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. Nat Commun. 2017; 8: 15729.

[77] Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharmacol Sci. 2017; 38: 226-56.

[78] Ruan W, Wang Y, Ma Y, Xing X, Lin J, Cui J, et al. HSP60, a protein downregulated by IGFBP7 in colorectal carcinoma. J Exp Clin Cancer Res. 2010; 29: 41.

[79] Kang SM, Kim SJ, Kim JH, Lee W, Kim GW, Lee KH, et al. Interaction of hepatitis C virus core protein with Hsp60 triggers the production of reactive oxygen species and enhances TNF-α-mediated apoptosis. Cancer Lett. 2009; 279: 230-7.

[80] Chaiwatanasirikul KA, Sala A. The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death Dis. 2011; 2: e219.

[81] Haron NH, Hanif MEA, Manaf MRA, Yaakub JA, Harun R, Mohamed R, et al. Microsatellite instability and altered expressions of MLH1 and MSH2 in gastric cancer. Asian Pac J Cancer Prev. 2019; 20: 509-17.

[82] Cacev T, Zapletal E, Musani V, Rako I, Loncar B, Aralica G, et al. Analysis of MSH2 loss of heterozygosity, expression, and IVS10+12G>A polymorphism in sporadic colon cancer . Anticancer Res. 2018; 38: 2841-8.

[83] Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, et al. Identification of a tumor-specific allo-HLA-restricted γδTCR. Blood Adv. 2019; 3: 2870-82.

[84] Story JY, Zoine JT, Burnham RE, Hamilton JAG, Spencer HT, Doering CB, et al. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia . Cytotherapy. 2021; 23: 12-24.

[85] Leslie DS, Vincent MS, Spada FM, Das H, Sugita M, Morita CT, et al. CD1-mediated γ/δ T cell maturation of dendritic cells. J Exp Med. 2002; 196: 1575-84.

[86] Kaminski H, Marsères G, Cosentino A, Guerville F, Pitard V, Fournié JJ, et al. Understanding human γδ T cell biology toward a better management of cytomegalovirus infection. Immunol Rev. 2020; 298: 264-88.

[87] Mo C, Dai Y, Kang N, Cui L, He W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J Biol Chem. 2012; 287: 19242-54.

[88] Zhao H, Xi X, Cui L, He W. CDR3δ-grafted γ9δ2T cells mediate effective antitumor reactivity. Cell Mol Immunol. 2012; 9: 147-54.

[89] He K, You H, Li Y, Cui L, Zhang J, He W. TCRγ4δ1-engineered αβ T cells exhibit effective antitumor activity. Mol Med. 2016; 22: 519-29.